CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SOGA1 (ImmuneEditome ID:140710)

1. Gene summary of enriched editing regions for SOGA1

check button Gene summary
Gene informationGene symbol

SOGA1

Gene ID

140710

GeneSynonymsC20orf117|KIAA0889|SOGA
GeneCytomap

20q11.23

GeneTypeprotein-coding
GeneDescriptionprotein SOGA1|SOGA family member 1|suppressor of glucose by autophagy|suppressor of glucose from autophagy|suppressor of glucose, autophagy-associated protein 1
GeneModificationdate20230329
UniprotIDX6R3R3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr20:36781242-36782851:-ENST00000237536.7ENSG00000149639.13SOGA1UTR3(AATA)n,MER5A,FLAM_C,AluSx,AluSz,MIRcchr20:36781242-36782851:-.alignment
chr20:36787196-36791259:-ENST00000237536.7ENSG00000149639.13SOGA1intronicAluSz,AluSg4,L1M5,L1MC5a,MLT2B4,FRAM,FLAM_C,AluSx,AluSz6,AluSx3,MIR,AluY,AluSp,AluYc,AluSc8chr20:36787196-36791259:-.alignment
chr20:36787196-36791259:-ENST00000279034.9ENSG00000149639.13SOGA1intronicAluSz,AluSg4,L1M5,L1MC5a,MLT2B4,FRAM,FLAM_C,AluSx,AluSz6,AluSx3,MIR,AluY,AluSp,AluYc,AluSc8chr20:36787196-36791259:-.alignment
chr20:36787196-36791259:-ENST00000465671.1ENSG00000149639.13SOGA1intronicAluSz,AluSg4,L1M5,L1MC5a,MLT2B4,FRAM,FLAM_C,AluSx,AluSz6,AluSx3,MIR,AluY,AluSp,AluYc,AluSc8chr20:36787196-36791259:-.alignment
chr20:36794812-36795742:-ENST00000237536.7ENSG00000149639.13SOGA1intronicAluSx,AluJrchr20:36794812-36795742:-.alignment
chr20:36794812-36795742:-ENST00000279034.9ENSG00000149639.13SOGA1intronicAluSx,AluJrchr20:36794812-36795742:-.alignment
chr20:36794812-36795742:-ENST00000465671.1ENSG00000149639.13SOGA1intronicAluSx,AluJrchr20:36794812-36795742:-.alignment
chr20:36807780-36807997:-ENST00000237536.7ENSG00000149639.13SOGA1intronicAluSz,AluYchr20:36807780-36807997:-.alignment
chr20:36807780-36807997:-ENST00000279034.9ENSG00000149639.13SOGA1intronicAluSz,AluYchr20:36807780-36807997:-.alignment
chr20:36807780-36807997:-ENST00000465671.1ENSG00000149639.13SOGA1intronicAluSz,AluYchr20:36807780-36807997:-.alignment
chr20:36839951-36840155:-ENST00000237536.7ENSG00000149639.13SOGA1intronicAluSx1chr20:36839951-36840155:-.alignment
chr20:36839951-36840155:-ENST00000279034.9ENSG00000149639.13SOGA1intronicAluSx1chr20:36839951-36840155:-.alignment
chr20:36841747-36842783:-ENST00000237536.7ENSG00000149639.13SOGA1intronic(GT)n,AluSx1,AluJb,L2achr20:36841747-36842783:-.alignment
chr20:36841747-36842783:-ENST00000279034.9ENSG00000149639.13SOGA1intronic(GT)n,AluSx1,AluJb,L2achr20:36841747-36842783:-.alignment
chr20:36849080-36850518:-ENST00000237536.7ENSG00000149639.13SOGA1intronicAluSp,AluJb,AluSzchr20:36849080-36850518:-.alignment
chr20:36849080-36850518:-ENST00000279034.9ENSG00000149639.13SOGA1intronicAluSp,AluJb,AluSzchr20:36849080-36850518:-.alignment


Top

2. Tumor-specific enriched editing regions for SOGA1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr20:36781242-36782851:-LUSCEER2.7429e-03image
ENSG00000149639.13,SOGA1LUSCEAG1.9986e-03image
chr20:36781242-36782851:-THCAEER2.0192e-04image
ENSG00000149639.13,SOGA1THCAEAG1.2721e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000149639.13,SOGA1SKCMEAG1.8036e-021.9380e-021.4495e+01image

Top

3. Enriched editing regions and immune related genes for SOGA1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:36781242-36782851:-OVEERENSG00000164713,BRI30.19102.8160e-028.1837e-120.4003imageNEIF4A3;GTF2F1;HNRNPC;IGF2BP2;U2AF1NAT_cells_CD8GSVA_HALLMARK_MITOTIC_SPINDLE
chr20:36781242-36782851:-UVMEERENSG00000175538,KCNE3-0.49881.8083e-032.6997e-04-0.4282imageNEIF4A3;IGF2BP2;U2AF1NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for SOGA1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr20:36781242-36782851:-
PRADEERIRENSG00000196914.4chr11120477446:120477526:120478155:1204783890.16204.5738e-025.1239e-180.4142imageNEIF4A3;GTF2F1;HNRNPC;IGF2BP2;U2AF1ARHGEF12T_cells_CD8GSVA_HALLMARK_MITOTIC_SPINDLE
chr20:36781242-36782851:-
TGCTEERA3ENSG00000107186.12chr913123152:13123271:13121738:13121932:13121738:13122170-0.41002.0862e-041.5771e-05-0.4133imageNEIF4A3;GTF2F1;HNRNPC;IGF2BP2;U2AF1NA
chr20:36781242-36782851:-
TGCTEERESENSG00000107186.12chr913121745:13121932:13122086:13122170:13123152:131232710.40632.1831e-042.2199e-050.4105imageNEIF4A3;GTF2F1;HNRNPC;IGF2BP2;U2AF1NA
ENSG00000149639.13,SOGA1
TGCTEAGMEXENSG00000127527.9chr1916361888:16361984:16377121:16377254:16386170:16386231:16392303:163924400.37301.0170e-021.6160e-060.4217imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;SF3A3;SF3B4;SLBP;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAGEPS15L1T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr20:36781242-36782851:-
TGCTEERA3ENSG00000111271.10chr12111744642:111745043:111746189:111746249:111746143:1117462490.30032.7088e-022.9058e-060.4504imageNEIF4A3;GTF2F1;HNRNPC;IGF2BP2;U2AF1NAT_cells_follicular_helperGSVA_HALLMARK_GLYCOLYSIS
ENSG00000149639.13,SOGA1
TGCTEAGA3ENSG00000107186.12chr913123152:13123271:13121738:13121932:13121738:13122170-0.34372.0099e-032.5089e-05-0.4006imageNADAR;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZFP36;ZNF184NA
chr20:36781242-36782851:-
TGCTEERIRENSG00000127838.9chr2218270391:218270602:218271423:2182715490.32321.7845e-025.1977e-050.4131imageNEIF4A3;GTF2F1;HNRNPC;IGF2BP2;U2AF1NAT_cells_CD4_naiveGSVA_HALLMARK_ALLOGRAFT_REJECTION
ENSG00000149639.13,SOGA1
TGCTEAGA3ENSG00000125846.11chr2018306318:18306393:18315068:18315106:18315071:183151060.27614.6118e-023.2073e-050.4069imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMast_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
ENSG00000149639.13,SOGA1
TGCTEAGA5ENSG00000115170.9chr2157799428:157799500:157818384:157818468:157818268:157818468-0.26094.0403e-021.6707e-05-0.4049imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;SF3A3;SF3B4;SLBP;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184ACVR1Macrophages_M2GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000149639.13,SOGA1
UVMEAGA3ENSG00000105662.11chr1918765403:18765528:18768742:18768793:18768484:187687930.49272.2589e-021.5667e-040.4427imageNADAR;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;SF3A3;SF3B4;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_FATTY_ACID_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for SOGA1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr20:36781242-36782851:-ACCEERMast_cells_resting1.3564e-020.3071image
ENSG00000149639.13,SOGA1ACCEAGMast_cells_resting1.9068e-020.2901image
chr20:36781242-36782851:-BLCAEERDendritic_cells_resting2.8632e-030.2175image
ENSG00000149639.13,SOGA1BLCAEAGDendritic_cells_resting1.7348e-020.1681image
chr20:36849080-36850518:-BRCAEERMacrophages_M01.9062e-020.4654image
ENSG00000149639.13,SOGA1CESCEAGPlasma_cells8.2303e-030.1953image
ENSG00000149639.13,SOGA1CHOLEAGMast_cells_resting6.4044e-030.5749image
chr20:36781242-36782851:-COADEERB_cells_memory1.1240e-020.2137image
ENSG00000149639.13,SOGA1COADEAGDendritic_cells_activated9.4298e-040.2727image
chr20:36781242-36782851:-ESCAEERNeutrophils2.2366e-020.1828image
chr20:36787196-36791259:-ESCAEERDendritic_cells_resting7.5931e-030.3501image
chr20:36849080-36850518:-ESCAEERT_cells_follicular_helper2.9486e-020.3248image
ENSG00000149639.13,SOGA1ESCAEAGNeutrophils5.5339e-030.2211image
chr20:36781242-36782851:-GBMEERDendritic_cells_activated1.3355e-020.2023image
ENSG00000149639.13,SOGA1GBMEAGDendritic_cells_activated1.2834e-020.2028image
chr20:36781242-36782851:-HNSCEERT_cells_CD4_memory_activated4.9142e-03-0.1440image
ENSG00000149639.13,SOGA1HNSCEAGT_cells_CD4_memory_activated6.3880e-03-0.1382image
chr20:36781242-36782851:-KIRPEERMast_cells_resting3.0913e-030.2616image
ENSG00000149639.13,SOGA1KIRPEAGMast_cells_resting1.2742e-030.2817image
ENSG00000149639.13,SOGA1LAMLEAGNK_cells_resting4.1193e-020.2099image
chr20:36781242-36782851:-LGGEERDendritic_cells_resting6.3104e-030.1214image
ENSG00000149639.13,SOGA1LGGEAGDendritic_cells_resting1.1090e-020.1122image
chr20:36781242-36782851:-LIHCEEREosinophils1.8113e-040.6231image
ENSG00000149639.13,SOGA1LIHCEAGEosinophils1.5452e-020.4062image
chr20:36781242-36782851:-LUADEERMacrophages_M23.0344e-020.1263image
ENSG00000149639.13,SOGA1LUADEAGMacrophages_M24.0307e-020.1171image
chr20:36781242-36782851:-MESOEERT_cells_CD81.2940e-030.4748image
ENSG00000149639.13,SOGA1MESOEAGT_cells_CD81.0314e-020.3829image
chr20:36794812-36795742:-OVEEREosinophils4.1188e-040.4451image
chr20:36849080-36850518:-OVEERT_cells_CD4_naive3.5599e-030.4046image
ENSG00000149639.13,SOGA1OVEAGT_cells_gamma_delta3.5530e-020.1255image
chr20:36781242-36782851:-PAADEERT_cells_CD4_memory_activated1.8550e-020.2564image
ENSG00000149639.13,SOGA1PAADEAGT_cells_CD4_memory_activated3.1226e-020.2339image
ENSG00000149639.13,SOGA1PCPGEAGB_cells_naive3.7870e-02-0.1974image
chr20:36781242-36782851:-PRADEERT_cells_gamma_delta4.1794e-020.1012image
chr20:36849080-36850518:-PRADEERDendritic_cells_resting1.3462e-020.4782image
ENSG00000149639.13,SOGA1READEAGNK_cells_activated2.3757e-02-0.2917image
chr20:36781242-36782851:-SARCEERMacrophages_M11.5668e-02-0.1682image
ENSG00000149639.13,SOGA1SARCEAGMacrophages_M21.1249e-020.1759image
chr20:36781242-36782851:-SKCMEERMacrophages_M04.2764e-020.0994image
ENSG00000149639.13,SOGA1SKCMEAGMacrophages_M02.1802e-020.1122image
chr20:36781242-36782851:-STADEERT_cells_CD4_memory_activated3.0250e-020.1266image
chr20:36787196-36791259:-STADEERT_cells_follicular_helper1.6736e-02-0.2668image
chr20:36794812-36795742:-STADEERMacrophages_M12.5988e-020.3610image
ENSG00000149639.13,SOGA1STADEAGNK_cells_activated4.2648e-020.1138image
chr20:36781242-36782851:-TGCTEERT_cells_regulatory_(Tregs)9.1028e-040.3105image
ENSG00000149639.13,SOGA1TGCTEAGDendritic_cells_activated9.7131e-040.2974image
chr20:36781242-36782851:-THCAEERNeutrophils7.2927e-03-0.1304image
ENSG00000149639.13,SOGA1THCAEAGNeutrophils2.3522e-02-0.1095image
chr20:36781242-36782851:-THYMEERMacrophages_M21.2723e-02-0.3905image
ENSG00000149639.13,SOGA1THYMEAGMacrophages_M25.5469e-03-0.4025image
chr20:36781242-36782851:-UCECEERNK_cells_activated3.1867e-02-0.2252image
ENSG00000149639.13,SOGA1UCECEAGNK_cells_activated4.8745e-02-0.1957image


Top

6. Enriched editing regions and immune gene sets for SOGA1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr20:36781242-36782851:-ACCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.3156e-020.2836image
ENSG00000149639.13,SOGA1ACCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.8710e-020.2571image
ENSG00000149639.13,SOGA1BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.6304e-02-0.1571image
ENSG00000149639.13,SOGA1BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.7861e-05-0.1342image
chr20:36781242-36782851:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER1.6311e-05-0.1358image
ENSG00000149639.13,SOGA1CESCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG9.9891e-03-0.1905image
chr20:36781242-36782851:-CESCGSVA_HALLMARK_APICAL_JUNCTIONEER1.3910e-02-0.1873image
ENSG00000149639.13,SOGA1CHOLGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.3472e-02-0.5300image
ENSG00000149639.13,SOGA1COADGSVA_HALLMARK_COAGULATIONEAG1.6849e-04-0.3085image
chr20:36781242-36782851:-COADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.5822e-04-0.2974image
ENSG00000149639.13,SOGA1DLBCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1716e-02-0.5515image
chr20:36781242-36782851:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.8606e-040.2866image
chr20:36794812-36795742:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER3.4728e-02-0.3391image
ENSG00000149639.13,SOGA1ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6496e-030.2500image
chr20:36849080-36850518:-ESCAGSVA_HALLMARK_MYOGENESISEER1.4631e-020.3617image
ENSG00000149639.13,SOGA1GBMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG7.0600e-040.2736image
chr20:36781242-36782851:-GBMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.2595e-040.2686image
ENSG00000149639.13,SOGA1HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.7190e-05-0.1979image
chr20:36781242-36782851:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5339e-03-0.1620image
chr20:36781242-36782851:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.1443e-03-0.2611image
ENSG00000149639.13,SOGA1KIRPGSVA_HALLMARK_MTORC1_SIGNALINGEAG6.8908e-04-0.2961image
chr20:36781242-36782851:-LAMLGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.0095e-020.2548image
ENSG00000149639.13,SOGA1LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.4702e-02-0.2065image
ENSG00000149639.13,SOGA1LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG6.5542e-07-0.2177image
chr20:36781242-36782851:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER7.9127e-05-0.1747image
ENSG00000149639.13,SOGA1LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.2242e-03-0.4534image
ENSG00000149639.13,SOGA1LUADGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.2667e-03-0.1505image
chr20:36781242-36782851:-LUADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.3564e-02-0.1320image
chr20:36781242-36782851:-LUSCGSVA_HALLMARK_APICAL_SURFACEEER6.4951e-03-0.1290image
ENSG00000149639.13,SOGA1LUSCGSVA_HALLMARK_APICAL_SURFACEEAG3.6932e-03-0.1369image
chr20:36781242-36782851:-MESOGSVA_HALLMARK_COAGULATIONEER1.3402e-020.3743image
ENSG00000149639.13,SOGA1MESOGSVA_HALLMARK_COAGULATIONEAG6.4152e-030.4048image
ENSG00000149639.13,SOGA1OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.0529e-030.1944image
chr20:36781242-36782851:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.1899e-040.2321image
chr20:36787196-36791259:-OVGSVA_HALLMARK_E2F_TARGETSEER1.5208e-020.2158image
ENSG00000149639.13,SOGA1PAADGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.7765e-02-0.2258image
ENSG00000149639.13,SOGA1PCPGGSVA_HALLMARK_PEROXISOMEEAG3.2692e-02-0.2029image
chr20:36781242-36782851:-PCPGGSVA_HALLMARK_PEROXISOMEEER3.7778e-02-0.2002image
ENSG00000149639.13,SOGA1PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.7346e-07-0.2386image
chr20:36849080-36850518:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER3.7453e-040.6450image
chr20:36781242-36782851:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER7.0034e-07-0.2436image
chr20:36781242-36782851:-READGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.5412e-02-0.2685image
ENSG00000149639.13,SOGA1SKCMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.6962e-06-0.2218image
chr20:36781242-36782851:-SKCMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.2067e-05-0.1994image
chr20:36794812-36795742:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4236e-020.3650image
ENSG00000149639.13,SOGA1STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.8351e-03-0.1741image
chr20:36781242-36782851:-STADGSVA_HALLMARK_MYC_TARGETS_V1EER6.4695e-040.1982image
chr20:36849080-36850518:-STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER4.9975e-020.2480image
chr20:36781242-36782851:-TGCTGSVA_HALLMARK_G2M_CHECKPOINTEER1.3655e-02-0.2335image
ENSG00000149639.13,SOGA1TGCTGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG5.8110e-03-0.2504image
chr20:36781242-36782851:-THCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.4331e-04-0.1841image
ENSG00000149639.13,SOGA1THCAGSVA_HALLMARK_UV_RESPONSE_DNEAG6.3515e-06-0.2163image
chr20:36781242-36782851:-THYMGSVA_HALLMARK_KRAS_SIGNALING_UPEER1.0171e-03-0.5001image
ENSG00000149639.13,SOGA1THYMGSVA_HALLMARK_DNA_REPAIREAG1.0170e-020.3753image
chr20:36781242-36782851:-UCECGSVA_HALLMARK_ADIPOGENESISEER5.8183e-040.3538image
ENSG00000149639.13,SOGA1UCECGSVA_HALLMARK_ADIPOGENESISEAG2.0839e-030.3014image
chr20:36781242-36782851:-UCSGSVA_HALLMARK_MYC_TARGETS_V2EER1.0251e-020.3875image
ENSG00000149639.13,SOGA1UCSGSVA_HALLMARK_MYC_TARGETS_V2EAG8.5040e-030.3964image
chr20:36781242-36782851:-UVMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.8099e-02-0.2664image
ENSG00000149639.13,SOGA1UVMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.5838e-02-0.2916image


Top

7. Enriched editing regions and drugs for SOGA1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000149639.13,SOGA1ACCDMOGEAG9.3963e-030.3199image
chr20:36781242-36782851:-ACCDMOGEER8.7363e-030.3252image
chr20:36781242-36782851:-BLCAGSK.650394EER3.3203e-02-0.1562image
ENSG00000149639.13,SOGA1BLCAAG.014699EAG3.9131e-02-0.1460image
chr20:36849080-36850518:-BRCAKIN001.135EER2.5631e-02-0.4455image
chr20:36781242-36782851:-BRCAA.770041EER1.1903e-04-0.1215image
ENSG00000149639.13,SOGA1BRCABryostatin.1EAG3.8601e-04-0.1113image
chr20:36781242-36782851:-CESCJNJ.26854165EER6.2538e-030.2077image
ENSG00000149639.13,SOGA1CESCBIRB.0796EAG6.9024e-030.1996image
ENSG00000149639.13,SOGA1CHOLDasatinibEAG1.2953e-020.5325image
ENSG00000149639.13,SOGA1COADAZ628EAG2.1948e-030.2532image
chr20:36781242-36782851:-COADCI.1040EER9.1550e-030.2195image
ENSG00000149639.13,SOGA1DLBCBMS.536924EAG1.4613e-03-0.6624image
chr20:36849080-36850518:-ESCAEHT.1864EER4.7092e-03-0.4139image
ENSG00000149639.13,SOGA1ESCACCT007093EAG1.6243e-050.3377image
chr20:36781242-36782851:-ESCACCT007093EER3.6532e-060.3610image
chr20:36794812-36795742:-ESCABAY.61.3606EER7.7760e-030.4200image
ENSG00000149639.13,SOGA1GBMLenalidomideEAG2.0657e-030.2496image
chr20:36781242-36782851:-GBMLenalidomideEER3.0854e-030.2409image
ENSG00000149639.13,SOGA1HNSCAMG.706EAG8.5245e-03-0.1334image
chr20:36781242-36782851:-HNSCAMG.706EER3.1697e-03-0.1510image
chr20:36781242-36782851:-KIRCGefitinibEER3.8142e-020.1198image
ENSG00000149639.13,SOGA1KIRCEHT.1864EAG2.6586e-020.1266image
ENSG00000149639.13,SOGA1KIRPBIBW2992EAG3.1472e-03-0.2591image
chr20:36781242-36782851:-KIRPBIBW2992EER6.5781e-03-0.2409image
chr20:36781242-36782851:-LAMLKU.55933EER4.0479e-02-0.2254image
chr20:36781242-36782851:-LGGBMS.536924EER2.8820e-05-0.1852image
ENSG00000149639.13,SOGA1LGGBMS.536924EAG9.3194e-08-0.2337image
ENSG00000149639.13,SOGA1LIHCAZD6482EAG6.1541e-060.6830image
chr20:36781242-36782851:-LIHCAZ628EER1.3547e-02-0.4387image
ENSG00000149639.13,SOGA1LUADA.770041EAG1.2270e-02-0.1428image
chr20:36781242-36782851:-LUADA.770041EER1.2067e-02-0.1462image
ENSG00000149639.13,SOGA1LUSCCyclopamineEAG1.3899e-020.1163image
chr20:36781242-36782851:-LUSCDMOGEER1.9729e-020.1106image
ENSG00000149639.13,SOGA1MESOMG.132EAG1.1443e-03-0.4743image
chr20:36781242-36782851:-MESOMG.132EER2.0555e-03-0.4572image
chr20:36849080-36850518:-OVCGP.60474EER5.1014e-030.3901image
chr20:36781242-36782851:-OVMG.132EER9.6366e-06-0.2662image
chr20:36787196-36791259:-OVBMS.536924EER1.1049e-020.2257image
ENSG00000149639.13,SOGA1OVCEP.701EAG6.4431e-04-0.2024image
chr20:36849080-36850518:-PRADKU.55933EER1.4584e-020.4734image
ENSG00000149639.13,SOGA1PRADBMS.536924EAG5.4235e-04-0.1669image
chr20:36781242-36782851:-PRADBMS.536924EER1.4081e-04-0.1881image
ENSG00000149639.13,SOGA1READBortezomibEAG2.5828e-020.2877image
chr20:36781242-36782851:-READBortezomibEER2.1485e-020.3067image
ENSG00000149639.13,SOGA1SARCJNK.Inhibitor.VIIIEAG1.0319e-020.1779image
ENSG00000149639.13,SOGA1SKCMBI.2536EAG4.8071e-030.1377image
chr20:36781242-36782851:-SKCMBI.2536EER2.7355e-030.1465image
chr20:36781242-36782851:-STADAS601245EER4.0359e-050.2374image
ENSG00000149639.13,SOGA1STADAS601245EAG4.5584e-050.2266image
chr20:36794812-36795742:-STADAS601245EER1.5737e-030.4952image
chr20:36849080-36850518:-STADCytarabineEER4.8661e-02-0.2494image
ENSG00000149639.13,SOGA1TGCTElesclomolEAG1.8201e-02-0.2153image
chr20:36781242-36782851:-TGCTBMS.536924EER2.2382e-03-0.2872image
chr20:36781242-36782851:-THCABMS.536924EER9.1178e-04-0.1609image
ENSG00000149639.13,SOGA1THCAEmbelinEAG1.0774e-070.2534image
ENSG00000149639.13,SOGA1THYMA.443654EAG1.8549e-03-0.4468image
chr20:36781242-36782851:-THYMGW843682XEER3.0921e-03-0.4562image
chr20:36781242-36782851:-UCECIPA.3EER2.0691e-040.3796image
ENSG00000149639.13,SOGA1UCECIPA.3EAG3.4724e-040.3474image
ENSG00000149639.13,SOGA1UCSAZD6482EAG1.0891e-030.4812image
chr20:36781242-36782851:-UCSAZD6482EER2.9765e-030.4424image
chr20:36781242-36782851:-UVMErlotinibEER2.3343e-02-0.2748image
ENSG00000149639.13,SOGA1UVMErlotinibEAG1.5711e-02-0.2919image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType